Basiliximab

Indications

Basiliximab is used for: Acute graft rejection in renal transplantation

Adult Dose

Intravenous Prophylaxis of Renal Transplant Rejection 20 mg IV within 2 hr prior to transplant surgery, THEN 20 mg IV 4 days after transplant Used in regimen containing cyclosporine and corticosteroids

Child Dose

Prophylaxis of Renal Transplant Rejection >35 kg: Administer as in adults; 20 mg IV within 2 hr prior to transplant surgery, THEN, 20 mg IV 4 days after transplant <35 kg: 10 mg IV within 2 hr prior to transplant surgery, THEN 10 mg IV 4 days after transplant Used in regimen containing cyclosporine and corticosteroids

Renal Dose

Administration

IV Preparation Reconstitute vials with 5 mL SWI Dilute reconstituted contents in 50 mL NS or D5W IV Administration For central or intravenous administration only Infuse over 20-30 min

Contra Indications

Hypersensitivity to basiliximab and murine proteins.

Precautions

Pregnancy and lactation. Re-exposure to a subsequent course of therapy of basiliximab. Lactation: Unknown whether excreted in milk; because of the potential for adverse reactions, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Pregnancy-Lactation

Pregnancy Category: B Lactation: Unknown whether excreted in milk; because of the potential for adverse reactions, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Interactions

Immunosuppressives other than ciclosporin and corticosteroids may increase the potential for over-immunosuppression.

Adverse Effects

Side effects of Basiliximab : Peripheral oedema, hypertension, atrial fibrillation; fever, headache, insomnia, pain; wound complication, acne; hypokalaemia, hyperglycaemia, hyperuricaemia, hypophosphataemia, hypercholesterolaemia; GI effects; UTI; anaemia; tremor; dyspnoea, infection. Rarely, hypersensitivity and anaphylactoid-type reactions.

Mechanism of Action

Basiliximab, a chimeric murine/human monoclonal antibody, blocks the ?-chain of the interleukin-2 receptor complex on the surface of activated T-lymphocytes.